30.89MMarket Cap-0.90P/E (TTM)
1.100High0.979Low401.58KVolume1.010Open0.987Pre Close410.82KTurnover1.48%Turnover RatioLossP/E (Static)31.57MShares3.39952wk High0.90P/B26.57MFloat Cap0.81052wk Low--Dividend TTM27.15MShs Float13.812Historical High--Div YieldTTM12.31%Amplitude0.810Historical Low1.023Avg Price1Lot Size
Opus Genetics Stock Forum
Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy
Thursday, 19th December at 8:00 am
Agreement Reached on Primary Endpoint and Phase 3 Trial Design
Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering
FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the tre...
📊⚡️📊
No comment yet